It happened: Dems reach drug pricing deal © Getty Images After several days (weeks? months?) of furious negotiating, Democrats said they have come to an agreement on a plan to lower prescription drug prices, seemingly solving one of the major stumbling blocks on the road to a vote on the $1.75 trillion Build Back Better legislation. The agreement is less far-reaching than earlier Democratic proposals, but it still represents progress on an issue the party has campaigned on for years. Details: The agreement would allow Medicare to negotiate drug prices in limited instances, prevent drug companies from raising prices faster than inflation and cap out-of-pocket costs for seniors on Medicare at $2,000 per year. One of the key compromises leading to a deal was limiting the scope of Medicare's ability to negotiate lower drug prices, which has long been a signature Democratic proposal. Lawmakers agreed to limit Medicare's ability to negotiate to older drugs that no longer have "exclusivity," meaning the period when they are protected from competition. Earlier versions of Democratic bills would have allowed negotiation for newer drugs, too. The deal would allow negotiation after nine years for many drugs, known as small molecule drugs, and after 12 years for more complex drugs known as biologics, according to a summary obtained by The Hill. If drug companies refuse to negotiate, they would face an excise tax as a punishment, a provision that has been controversial with some moderates. Medicare could negotiate up to 10 drugs starting in 2025 and up to 20 drugs in 2028 and beyond, according to the summary. Insulin copays would be capped at $35 per month. Read more here. |
No comments:
Post a Comment